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Abstract
Background: Hepatic steatosis, a common condition associated with insulin resistance and excess body
weight, is reported to be associated with an increased risk for perioperative mortality in patients undergoing
resection of colorectal liver metastases (CLM), but its impact upon longterm survival is less well documented.
Methods: The effects of background liver pathology, categorized as ‘normal’, ‘with steatosis’ and
‘other’, on perioperative mortality, overall survival (OS) and cancer-specific survival (CSS) were assessed
in patients undergoing resection for CLM according to data maintained in the LiverMetSurvey database.
As preoperative chemotherapy may confound the effects of steatosis, patients who had been given
preoperative chemotherapy were excluded. Survival analyses included log-rank tests for comparisons,
and multivariate Cox models, including well-established prognosticators.
Results: Of 5853 patients who underwent first-time liver resection without preoperative chemotherapy,
1793 (30.6%) had background steatosis. Rates of 90-day perioperative mortality in patients with normal,
steatosis and other pathologies were 2.8%, 2.1% and 4.9%, respectively. Steatosis was associated with
improved 5-year OS (47.4% versus 43.0%; log rank, P = 0.0017) and CSS (56.1% versus 50.3%; P =
0.002) compared with normal background liver. After adjustments, the survival advantage associated with
steatosis remained (hazard ratio = 0.806, 95% confidence interval 0.717–0.905 for CSS).
Discussion: The paradoxical survival advantage observed in patients with steatosis undergoing liver
resection for CLM generates a hypothesis that peri-diagnosis of excess body adiposity has a survival
protective effect that warrants further research.
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Introduction
Hepatic steatosis is a pathological process characterized by an
abnormal deposition of fat within the liver, estimated to occur in
a third of the Western adult population.1,2 It may progress to
steatohepatitis and ultimately cirrhosis, conditions which make
up a spectrum of hepatic pathologies encompassed by the
umbrella term ‘non-alcoholic fatty liver disease’.3,4 Within the
general population, steatosis is most commonly associated with
a high body mass index (BMI) and insulin resistance.3,5 The
diagnosis is conventionally made histologically, when 5% of
liver tissue is seen to contain fat.4,5 As the presence of steatosis
mirrors the presence of excess body adiposity, and the latter is an
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established risk factor for incident cancer,6 including colorectal
cancer,7 it is reasonable to hypothesize that steatosis is an adverse
factor for outcome after resection of colorectal liver metastases
(CLM).
In patients undergoing resection of CLM, background liver
steatosis may additionally be caused by preoperative chemo-
therapy (notably irinotecan-containing regimens),8,9 in which the
histological appearance is similar to that in excess body adiposity.
Steatosis is a relatively common finding in liver resection speci-
mens, although rates vary from 18% to 56% depending on the
diagnostic criteria used,10–12 and several reports have described an
association with increased risk for perioperative morbidity, par-
ticularly in patients undergoing a major liver resection11,13–15
(removal of three or more segments according to the Brisbane
2000 Terminology of Liver Anatomy and Resections16). A recent
meta-analysis17 concluded that moderate/severe steatosis (30%)
was associated with an increased risk for perioperative mortality,
but apart from the study by Behrns et al.13 (published at a time
when it was uncommon to administer preoperative chemo-
therapy), all the studies in this analysis17 grouped together patients
with steatosis regardless of whether they had or had not received
preoperative chemotherapy.11,14,15,17 If the confounding effects of
preoperative chemotherapy are not taken into account, it is
unclear whether obesity-related steatosis per se impacts adversely
on early outcome. In terms of longterm survival, to date only three
studies have evaluated the impact of steatosis or steatohepatitis.
One of these included cancer types other than CLM;14 the other
two were small but limited to CLM and reported non-significant
reductions in, respectively, median overall survival (OS) in
patients with steatosis,12 and median recurrence-free survival in
patients with severe grade steatohepatitis.18 As with studies of
early outcome, these studies of longterm outcome did not take
account of the confounding effects of preoperative chemotherapy.
This study aimed to use data from the international registry,
LiverMetSurvey, to assess the effect of background liver steatosis
on perioperative and longterm survival in patients undergoing
resection of CLM. To control for the confounding effects of
chemotherapy, and to assess survival in relation to that in steatosis
arising from obesity-related causes, the analysis was limited to
patients who did not receive preoperative chemotherapy.
Materials and methods
Database
LiverMetSurvey (http://www.livermetsurvey.org) is a prospective
international database of patients with metastatic colorectal
cancer undergoing surgery for CLM that comprises data volun-
tarily registered by 235 centres across 63 countries (many centres
started data collection in the early 1990s).19–21 The register was
developed both to prospectively collect essential clinical data on a
multi-institution basis and to evaluate clinical outcome and prog-
nostic factors on a large scale. Data concerning patient demo-
graphics, the primary tumour, the number, size and location(s) of
liver metastases, the type of hepatic resection, postoperative com-
plications, the time and nature of recurrence, and survival are
entered into a register, using a standardized questionnaire that is
completed online.
Histological categorization
The local clinical team documents whether background liver his-
tology was normal or abnormal. If it was abnormal, the team
completes a tick-box list to indicate whether this abnormality
reflected ‘congestion’, ‘fibrosis’, ‘nodular regenerative hyperplasia’,
‘steatosis’ or ‘other’. More than one box may be ticked and free text
can be used to describe ‘other’ pathology. Guidance on how to
classify abnormal liver histology is not provided and thus classi-
fication methods rely on the local pathology reporting system.
For the purposes of this analysis, background liver histology
was classified into three categories: ‘normal’; ‘steatosis’, and ‘other’
(hepatic pathologies other than steatosis, such as ‘congestion’,
‘fibrosis’, ‘nodular regenerative hyperplasia’). Combinations of
more than one pathology category were re-allocated so that any
patients categorized with combined pathologies were allocated to
the steatosis category. For example, cases of ‘steatosis + fibrosis’ or
free-text documentation of ‘steatohepatitis’ were placed in the
‘steatosis’ category; free-text phrases such as ‘sinusoidal obstruc-
tion syndrome’ and ‘vascular’ were re-coded as ‘congestion’ and
placed in the ‘other’ category.
Analysis inclusion
The primary focus of the analysis was patients undergoing first-
time resection with information on background liver histology.
The following patients were excluded: those with incomplete
chemotherapy data; non-surgical patients; patients undergoing
repeat resections (as it was felt that such patients would have an
abnormal liver pathology because of regeneration and/or would
have received numerous previous cycles of chemotherapy);
patients without background liver histology, and patients entered
as undergoing first surgery before 1990. To address potential con-
founding caused by chemotherapy-induced liver injury, the vari-
able ‘preoperative chemotherapy’ was used to identify a group of
patients free from liver-directed chemotherapy. Although not con-
ventionally regarded as a risk factor for chemotherapy-induced
liver injury, the ‘chemotherapy post-colectomy’ variable was used
to address the possible confounding effect of adjuvant bowel
chemotherapy delivered prior to liver resection.
Follow-up
Data recorded on the ‘latest news’ page were extracted to ascertain
follow-up. Individual follow-up data are inputted sequentially to
document whether a patient is alive or not, and if the patient is not
alive, whether his or her death was cancer-related.
Statistical analysis
The primary outcome measures in this analysis were: 90-day peri-
operative mortality (chosen because traditional 30-day mortality
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does not capture patients in whom death from postoperative liver
failure occurs outside this time limit9,22); OS, and cancer-specific
survival (CSS).
Differences in baseline characteristics across the background
liver histology categories were explored using standard
approaches for continuous (Kruskal–Wallis test) and categorical
(chi-squared test for multiple categories) variables as appropriate.
Perioperative mortality was expressed using crude rates. Odds
ratios (ORs) and 95% confidence intervals (CIs) were derived
from comparative tests using logistic regression models with
adjustments for age, gender and year. These models were extended
to test for interactions between steatosis and extent of resection as
multiplicative products. The Cochran–Armitage test was used to
test for trends across ordered groups (e.g. time periods).
Kaplan–Meier curves were constructed for all time-to-event
outcome measures and compared across groups with the standard
log-rank test. Time zero was defined as the date of liver resection
surgery. Overall survival was defined as the time from first resec-
tion to death from any cause, and CSS was defined as time from
first resection to death from colorectal cancer.23 Cox models were
applied to assess whether steatosis was an independent prognostic
factor on OS and CSS. A seven-step approach advocated by
Hosmer and colleagues24 was used to force background histology
categories into the final model. Predictive accuracy and the cali-
bration of the models were tested using a concordance index
(C-statistic; values range from 0.5 to 1.0).
To test for confounding, covariates shown to independently
prognosticate for survival after resection for CLM according to
Rees and colleagues25 were used. These included: node positive
primary; more than three hepatic metastases; carcinoembryonic
(CEA) antigen level >60 ng/ml; tumour diameter of 5 cm; posi-
tive resection margin, and extrahepatic disease. This model was
chosen because six of the seven factors were available (informa-
tion on the differentiation of the primary tumour was not avail-
able) and the patients reported by Rees et al.25 were operated on
over a time period comparable with that of the LiverMetSurvey.
To take account of multiple testing, a P-value of <0.01 was con-
sidered to indicate statistical significance. All statistical analyses
were performed using stata Version 11.1 (StataCorp LP, College
Station, TX, USA).
Results
Overview
The LiverMetSurvey database included 16 779 procedure cases to
December 2011. From these, 5853 patients who underwent first
liver resections without preoperative chemotherapy from 1990
were identified. A flow diagram is shown in Fig. 1.
Baseline characteristics
Table 1 shows the baseline characteristics of the cohort for analy-
sis, categorized by pathological background as ‘normal’, ‘with stea-
tosis’ and ‘other’. The median age was 64.1 years (interquartile
range: 56–71 years) and the male : female ratio was approximately
3.5:2.0. The proportion of patients undergoing resection with
background steatosis was 30.6%; this increased from 27.2%
during 1990–1995 to 31.3% during 2006–2011, but this difference
fell short of statistical significance. Approximately equal numbers
of patients underwent minor and major resections. According to
the prognostic system described by Rees et al.,25 steatosis was more
common in the presence of the following factors: more than three
hepatic metastases (P < 0.0001); minimum margin of <1 mm (P =
0.007), and absence of extrahepatic disease (P = 0.003). Addition-
ally, steatosis was more commonly associated with metachronous
than synchronous resections (P < 0.001).
Perioperative mortality
A total of 160 deaths occurred within 90 days of first resection,
giving a crude mortality rate of 2.8% (Table 2). Rates of 90-day
LiverMet Survey
Until December 2011
n =16 779
First-time hepatic resection
with known background histology
1990–2011
n =10 182
Without preoperative
chemotherapy
n = 5853
Background liver histology
Incomplete chemotherapy data,
n = 32
Non-surgical, n = 1092  
Background histology unknown,
n =  3503
Repeat hepatectomy, n = 1736
Resection pre-1990, n = 234  
Preoperative chemotherapy,
n =  4329
Normal: n = 3522 (60.2%) 
Steatosis: n = 1793 (30.6%) 
Other pathologies: n = 538 (9.2%) 
Figure 1 Flow diagram illustrating the selection of the study cohort
from patients listed in the LiverMetSurvey database from 1990 to
December 2011
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Table 1 Characteristics of patients undergoing first-time hepatic resection for colorectal cancer metastases without preoperative chemo-
therapy, LiverMetSurvey 1990–2011
All patients Background histology P-value
Normal Steatosis Other
Total, n (%) All 5853 3522 (60.2) 1793 (30.6) 538 (9.2)
Age, years, median (IQR) Alla 64.1 (56–71) 63.9 (56–71) 64.5 (57–71) 64.1 (56–71) 0.238
Gender, n (%) Male 3594 2094 (58.3) 1157 (32.2) 343 (9.5) 0.001
Female 2259 1428 (63.2 636 (28.2) 195 (8.6)
Year band, n (%) 1990–1995 246 161 (65.5) 67 (27.2) 18 (7.3) 0.125
1996–2000 442 275 (62.2) 130 (29.4) 37 (8.4)
2001–2005 1410 876 (62.1) 419 (29.7) 115 (8.2)
2006–2011 3755 2210 (58.9) 1777 (31.3) 368 (9.8)
Type of resection, n (%) Minor (<3) 2620 1624 (62.0) 784 (29.9) 212 (8.1) 0.032
Major (3) 2687 1582 (58.9) 845 (31.5) 260 (9.7)
Unknown 546 (9.3)
Site of primary tumour, n (%) Colon 3499 2069 (59.1) 1096 (31.3) 334 (9.6) 0.014
Rectum 1824 1153 (63.2) 520 (28.5) 151 (8.3)
Colon and rectum 11
Unknown 519 (8.9)
Stage of primary tumour, n (%) T0/T1 117 69 (59.0) 36 (30.8) 12 (10.3) 0.883
T2 703 412 (58.6) 224 (31.9) 67 (9.5)
T3 3389 2041 (60.2) 1042 (30.8) 306 (9.0)
T4 878 530 (60.4) 258 (29.4) 90 (10.3)
Unknown 766 (13.0)
CEA at diagnosis, median (IQR) Allb 9.0 (3.4–31.0) 9.1 (3.3–32.0) 8.4 (3.5–28.0) 9.7 (3.5–38.3) 0.431
Synchronous or metachronous
disease, n (%)
Synchronous 2188 1355 (61.9) 596 (27.2) 237 (10.8) <0.001
Metachronous 2908 1718 (59.1) 949 (32.6) 241 (8.3)
Unknown 757 (12.9)
Unilobar or bilobar disease, n (%) Unilobar 4150 2520 (60.7) 1276 (30.8) 354 (8.5) 0.022
Bilobar 1600 945 (59.1) 481 (30.1) 174 (10.9)
Unknown 103 (1.8)
Nodal status of primary tumour, n (%) N0 1897 1169 (61.6) 582 (30.7) 146 (7.7) 0.019
N1/N2 3186 1908 (59.9) 958 (30.0) 320 (10.0)
Unknown 770 (13.1)
CEA at hepatectomy, median (IQR) Allc 9.0 (3.2–32) 9.2 (3.2–32.6) 8.5 (3.1–30.2) 8.1 (3–35.2) 0.634
Number of hepatic metastases, n (%) 3 4651 2863 (61.6) 1392 (29.9) 396 (8.5) <0.0001
>3 904 483 (53.4) 299 (33.1) 122 (13.5)
Unknown 280 (4.8)
Diameter of largest hepatic metastasis,
n (%)
<5 cm 3953 2353 (59.5) 1225 (31.0) 375 (9.5) 0.991
5 cm 1512 903 (59.7) 465 (30.8) 144 (9.5)
Unknown 387 (6.6)
Minimum margin of hepatic resection,
n (%)
<1 mm 641 345 (53.8) 226 (35.3) 70 (10.9) 0.007
1 mm 4413 2662 (60.3) 1345 (30.5) 406 (9.2)
Unknown 799 (13.7)
Extrahepatic disease at hepatectomy,
n (%)
Yes 526 328 (62.4) 149 (28.3) 49 (9.3) 0.003
No 976 527 (54.0) 362 (37.1) 87 (8.9)
Unknown 4351 (74.3)
aMissing age data in 17 patients.
bMissing CEA at time of initial diagnosis in 2615 patients.
cMissing CEA at time of hepatectomy data in 2385 patients.
IQR, interquartile range; CEA, carcinoembryonic antigen.
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perioperative mortality in patients with ‘normal’, ‘steatosis’ and
‘other’ pathologies were 2.8%, 2.1% and 4.9%, respectively. Peri-
mortality rates were explored by extent of surgery (major versus
minor resections according to Brisbane 2000 Terminology16);). In
general, a higher rate of perimortality occurred in patients under-
going major resections.
To explore this further and take account of differences in age
between background liver histology categories, logistic regression
models were generated and ORs derived. For all resections, the
occurrence of perioperative mortality did not increase in associa-
tion with steatosis, but did so significantly in association with
‘other’ pathologies (OR = 1.880, 95% CI 1.204–2.037; P = 0.005).
Stratification by extent of surgery did not materially influence
these findings and the test for interaction between steatosis and
extent of surgery was borderline significant (P = 0.039).
Longterm survival
Median follow-up in the entire cohort was 20 months. The 5-year
OS rate was 44.0% (95% CI 42.0–46.0) and 5-year CSS was 51.8%
(95% CI 49.7–54.0). By background liver histology, 5-year OS
rates in the ‘normal’, ‘steatosis’ and ‘other’ groups were 43.0%,
47.4% and 39.0%, respectively (Fig. 2a). The improvement in OS
in patients with steatosis compared with normal pathology was
significant (log rank test, P = 0.0017). Rates of 5-year CSS in
patients with ‘normal’, ‘steatosis’ and ‘other’ pathologies were
50.3%, 56.1% and 47.2%, respectively (Fig. 2b). Again, the
improvement in CSS in patients with steatosis compared with
normal pathologies was significant (log rank test, P = 0.002).
Cox models were used to test whether the improved CSS
observed with steatosis reflected confounding (Table 3). Model 1
adjusted for age, gender and year of surgery; the CSS advantage
associated with steatosis remained [hazard ratio (HR) = 0.840,
95% CI 0.749–0.943]. Model 2 was extended to include known
prognostic factors.25 In this model, the survival reduction associ-
ated with steatosis remained materially unchanged (HR = 0.806,
95% CI 0.717–0.905).
Internal validation
The robustness of the finding of a reductive effect of steatosis on
CSS was tested further using Cox models stratified by age and year
bands (Table 4). Hazard ratios were similar across these strata,
except for the >75 years age band. Additional subsamples taken
without replacement, in three sets, derived similar HR estimates
for steatosis.
Post-colectomy chemotherapy
Finally, the effect of previous adjuvant post-colectomy chemo-
therapy as a potential confounder was tested. A total of 2728
(46.6%) patients had received adjuvant chemotherapy prior to
liver resection as part of their treatment for primary colorectal
cancer; most patients had been given fluoropyrimidine-based
therapies. The risk estimate of steatosis on CSS after liver resection
was uninfluenced by the addition of whether or not adjuvant
chemotherapy had been administered prior to resection (HR =
0.833, 95% CI 0.742–0.936). In a sub-cohort of patients who had
received adjuvant chemotherapy for primary colorectal cancer
prior to liver resection and for whom complete data on the dates
of treatment were available (n = 1594), the test for interaction
between presence of steatosis and timing of adjuvant chemo-
therapy (>6 months versus <6 months prior to resection) was
non-significant (P = 0.754).
Discussion
Main findings
This analysis of a large international clinical database showed that,
in patients undergoing resection of CLM, without preoperative
Table 2 Crude rates and logistic regression models for 90-day perioperative mortality by background liver histology
Total Background histology P-value
Normal Steatosis Other pathologies
Mortality, numbers and crude rates, n (%)de
All resections 160 (2.76) 97 (2.77) 37 (2.08) 26 (4.91) 0.002a
Minor resection 49 (1.89) 33 (2.05) 9 (1.16) 7 (3.38) 0.084a
Major resection 95 (3.57) 59 (3.76) 21 (2.51) 15 (5.86) 0.034a
Logistic regression, odds ratio (95% CI)b Other versus referent
All resections 1.00 (referent) 0.740 (0.504–1.086) 1.880 (1.204–2.937) 0.005
Minor resection 1.00 (referent) 0.576 (0.273–1.217) 1.758 (0.756–4.086) 0.190
Major resection 1.00 (referent) 0.655 (0.395–1.086) 1.696 (0.941–3.055) 0.079
Test for interactionc 0.039
aChi-squared test for multiple categories.
bAll logistic regression models adjusted for age, gender and year.
cFor the test for interaction, other pathologies were excluded (i.e. the question was an interaction between steatosis and extent of resection).
dData missing on number of segments resected in 546.
eData missing on perioperative mortality in 47.
95% CI, 95% confidence interval.
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chemotherapy, steatosis in the background liver occurs in
approximately a third of cases. The presence of steatosis in this
setting was associated with no increase in perioperative mortality.
By contrast, steatosis – assumed here to reflect excess body adi-
posity – was associated with improved longterm OS and CSS, an
observation which remained robust after adjustment for well-
established prognostic factors. As a secondary finding, patients
with other types of liver pathology, including fibrosis, congestion
and regenerative nodular hyperplasia, were found to be at high
risk for perioperative mortality and worse longterm survival.
Comparison with the published literature
This is the largest analysis to date to evaluate the impact of back-
ground steatosis on short- and longterm survival. By contrast with
a meta-analysis performed by de Meijer et al.,17 a four-study
analysis of 1000 patients which found a 2.5-fold increase in peri-
operative mortality associated with steatosis of30%, the present
study found no such association. There may be several reasons for
these differences, including: (i) the de Meijer et al. meta-analysis17
included a mixture of chemotherapy-treated and chemotherapy-
naïve patients11,13–15 (steatosis may have divergent effects on early
outcomes in these two settings); (ii) the present study defined
perioperative mortality as death within 90 days of surgery,
whereas the definitions used in studies included in the meta-
analysis17 varied from death within 30 days,13 to death within 60
days or in-hospital mortality,14 death within 90 days 15 and death
before discharge;11 (iii) the LiverMetSurvey registry does not con-
sistently grade steatosis, whereas the de Meijer et al. meta-
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Figure 2 (a) Overall and (b) cancer-specific survival in the study cohort by background liver pathology
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analysis17 found significant differences in rates of perioperative
mortality in the context of steatosis of30%, but not in the more
common setting of milder grades of steatosis, and (iv) periopera-
tive mortality after liver resection for CLM is relatively rare: the
deaths reported in the small-sample studies included in the meta-
analysis by de Meijer et al.17 may have occurred by chance, whereas
the sample size in the present analysis includes more than five
times as many patients (5853 versus 1000) and three times as
many perioperative deaths (160 versus 49).
Other than one article, which was published in an era in which
it was uncommon to administer chemotherapy prior to resec-
tion,13 previous studies have regarded steatosis and steatohepatitis
after preoperative chemotherapy as equivalent to those seen in
patients who are chemotherapy-naïve.9,11,12,15,17 Although drug-
induced steatosis is indistinguishable on postoperative histology
from that seen in individuals who are obese or insulin-resistant,
the strong association between this liver injury pattern and
irinotecan-based chemotherapy reported previously8,9 implies
that separate pathological processes may be involved. There is a
need to learn more about how an individual’s metabolic risk
interacts with chemotherapy agents administered preoperatively.
The observation of a survival advantage associated with steato-
sis in the present analysis is paradoxical. This is set against the
findings of three previous studies (Table 5), which evaluated
either steatosis or steatohepatitis in this context and reported
findings of a general (albeit non-significant) trend towards
reduced survival. However, these studies, the largest of which
included only 485 patients14 (compared with 5853 in the present
series), pooled data for chemotherapy-treated and chemotherapy-
naïve patients and were probably underpowered. The observa-
tions derived in the present analysis are perhaps not very
surprising when they are considered alongside the findings of
other studies that have evaluated the impact of peri-diagnosis
obesity, which, in turn, is correlated with steatosis and longterm
survival.
Clinical implications
In the general population, liver fat deposition is strongly corre-
lated with visceral obesity and insulin resistance.5,26,27 The para-
doxical survival advantage observed in patients in the present
analysis generates a hypothesis that peri-diagnosis excess body
adiposity provides a survival protective effect that warrants
further research. Although it is conventional to view obesity (par-
ticularly visceral obesity) as an adverse factor at the diagnosis of
several diseases,28 for cancer, evidence to the contrary is starting to
emerge. In their analysis of body composition and outcome in
patients undergoing resection of CLM, van Vledder and col-
leagues29 found that visceral fat area had no effect on longterm
survival, whereas data from the CAIRO trial of chemotherapy in
Table 3 Cox proportional hazard model testing the impact of stea-
tosis on cancer-specific survival, with adjustments for prognostic
factors according to Rees et al.25
Covariates Hazard ratio 95% CI
Model 1a
Normal (referent) 1.00 (referent)
Steatosis 0.840 (0.749–0.943)
Other pathologies 1.106 (0.919–1.331)
Model 2a
Normal (referent) 1.00 (referent)
Steatosis 0.806 (0.717–0.905)
Other pathologies 1.037 (0.861–1.251)
Gender (male versus female) 1.066 (0.959–1.184)
Age (continuous variable: per year) 1.003 (0.998–1.008)
Nodal status of primary tumour
(N1/N2 versus N0)
1.559 (1.387–1.753)
CEA at hepatectomy (>60 ng/ml
versus 60 ng/ml)
1.324 (1.125–1.558)
Number of hepatic metastases (>3
versus 3)
1.537 (1.344–1.759)
Diameter of largest hepatic
metastasis (5 cm versus
<5 cm)
1.364 (1.215–1.532)
Minimum margin of hepatic
resection (1 mm versus
<1 mm)
1.515 (1.301–1.765)
Extrahepatic disease (yes versus
no)
1.277 (1.067–1.528)
aFor model 1, Harrell's C-statistic = 0.5489; for model 2, C = 0.6344.
95% CI, 95% confidence interval; CEA, carcinoembryonic antigen.
Model 1, age, gender, year and steatosis only. Only hazard ratios for
steatosis are shown.
Model 2, as above plus all other variables simultaneously.
Table 4 Internal validation of Cox model cancer-specific survival
findings tested against age and year bands, and random sampling
HR for steatosis
versus referent
95% CI
Age bandsa
<50 years 0.882 (0.640–1.216)
50–74 years 0.805 (0.908–1.399)
75 years 1.074 (0.774–1.489)
Year bandsb
1990–1995 0.899 (0.622–1.298)
1996–2000 0.897 (0.674–1.192)
2001–2005 0.779 (0.640–0.949)
2006–2011 0.871 (0.724–1.048)
Random subsamplingc
First sample (n = 1000) 0.832 (0.639–1.085)
Second sample (n = 1000) 0.753 (0.564–1.006)
Third sample (n = 2000) 0.712 (0.580–0.875)
aAdjusted for year and gender.
bAdjusted for age and gender.
cEach subsampling was mutually exclusive of the next.
HR, hazard ratio; 95% CI, 95% confidence interval.
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patients with metastatic colorectal cancer showed improved OS in
obese patients compared with those of normal weight.30 (The
authors of the latter study hypothesized that this outcome may
have reflected a superior nutritional reserve in obese patients.30) It
is too early to conclude that peri-diagnosis obesity is a good prog-
nosticator in metastatic colorectal cancer, but the issue warrants
further research.
Strengths and limitations
There are several strengths to this study and analysis. Firstly, the
large size of the overall database allowed the analysis to be
restricted to patients undergoing first-time liver resection without
preoperative chemotherapy, while maintaining an adequate
sample size. Secondly, the database captured many well-
established prognostic factors and the potential confounding of
adjuvant post-colectomy chemotherapy; these were included in
the Cox model, which showed the main findings to be materially
unaffected. Thirdly, the internal validity of the data (e.g. consist-
ency of ages and steatosis diagnoses per year) were tested and no
major deviations in parameters were found. Finally, fixed (by year
and age groups) and random sampling of three subgroups of the
main dataset were used and produced similar results.
This study has limitations. Firstly, a clinical database such as
that of the LiverMetSurvey is reliant upon the accuracy of data
entry. For example, pathology reporting is not standardized across
LiverMetSurvey centres and, in particular, the 5% cut-off value
used to make a diagnosis of steatosis4 has not subsequently been
applied with consistency in the wider literature.11,15 Steatosis was
captured as either present or absent, which prevented further
analysis according to grade or the presence of steatohepatitis.
Nonetheless, when steatosis is assessed using visual techniques, it
may be more appropriate to refer simply to its presence or absence
because considerable inter-rater variability for steatosis grade
exists even between expert pathologists (kappa scores: 0.64–
0.79).4 Biochemical and digital counting techniques generate
much more precise and reproducible results.31,32 Secondly, Liver-
MetSurvey lacks data on BMI, diabetes, alcohol consumption
history, and comorbidities (e.g. performance status or anaesthetic
assessment scores) and it would have been useful to examine how
these correlated with the presence or absence of steatosis and to
have investigated whether excess BMI or the presence of diabetes
impacted upon survival.
Unanswered questions and future research
The key unanswered question concerns whether or not there is
unmeasured residual confounding: examples suggested already
include BMI and other anthropometric measurements, metabolic
measurements and alcohol consumption, but extend to unmeas-
ured factors that may have favoured certain treatments (i.e. con-
founding by indication). Other residual confounding may include
as yet unmeasured allelic polymorphisms that interact with stea-
tosis and disease progression. The present findings should be rep-
licated in other settings. Examples may include observational
analyses within large trials with standardized treatment protocols
(thus reducing confounding by indication). In parallel with estab-
lishing the true clinical relationships, there is a need to consider
biological mechanisms, which are currently very much under-
studied in humans in terms of the fatty liver–tumour interface.
Given the projected increase in the numbers of patients eligible for
resection of CLM in the future,33 and a parallel increase in the
prevalence of steatosis in Western populations, better understand-
ing of this topic is likely to benefit many patients.
Table 5 Summary of literature review: effect of steatosis/steatohepatitis on survival after hepatic resection
Study Patients, n Survival Comments
Mixed: with and without preoperative chemotherapy
Kooby et al. (2003)a14 485 5-year overall survival: No statistically significant difference
Without steatosis: 45%
With steatosis: 38%
Pathak et al. (2010)12 102 Median survival: No statistically significant difference
Without steatosis: 32.3 months
With steatosis: 28.6 months
Tamandl et al. (2011)18 196 3-year recurrence-free survival: No statistically significant difference
NAS grades 0–2: 20.8%
NAS grades 3 and 4: 16.7%
NAS grades 5: 14.3%
Without chemotherapy
Present study 5853 5-year overall survival: Improved OS and CSS in steatosis patients
Without steatosis: 43.0% Multivariate HR for CSS = 0.806
With steatosis: 47.4%
aIncluded non-colorectal liver metastases resections (both benign and malignant).
NAS, Kleiner–Brunt non-alcoholic fatty liver disease activity score; OS, overall survival; CSS, cancer-specific survival; HR, hazard ratio.
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